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Due to their post-mitotic state, metabolic demands and often large polarised morphology, the function and survival
of neurons is dependent on an efficient cellular waste clearance system both for generation of materials for
metabolic processes and removal of toxic components. It is not surprising therefore that deficits in protein
clearance can tip the balance between neuronal health and death. Here we discuss how autophagy and lysosome-
mediated degradation pathways are disrupted in several neurological disorders. Both genetic and cell biological
evidence show the diversity and complexity of vesicular clearance dysregulation in cells, and together may
ultimately suggest a unified mechanism for neuronal demise in degenerative conditions. Causative and risk-
associated mutations in Alzheimer’s disease, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Parkinson’s
disease, Huntington’s disease and others have given the field a unique mechanistic insight into protein clearance
processes in neurons. Through their broad implication in neurodegenerative diseases, molecules involved in these
genetic pathways, in particular those involved in autophagy, are emerging as appealing therapeutic targets for
intervention in neurodegeneration.
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Neurodegenerative diseases are defined by the progres-
sive and irreversible destruction of neurons, with age-
associated cell death occurring through heterogeneous,
only partially defined mechanisms. A varied range of be-
havioural, cognitive and physiological symptoms are as-
sociated with neurodegenerative diseases, dependent on
the affected neuronal populations. The most common
neurodegenerative diseases broadly cause two primary
symptoms, cognitive decline such as the profound de-
mentia presented in Alzheimer’s disease (AD), and
motor system dysfunction such as the slowing of move-
ment and eventual paralysis seen in Parkinson’s disease
(PD). Almost without exception, effective preventative
therapeutics are unavailable for neurodegenerative dis-
eases, with only palliative treatments currently in use. As
with most neurological disorders [1] neurodegenerative
diseases are distributed globally with an increasing© The Author(s). 2019 Open Access This artic
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A paucity of effective treatments for neurodegenerative
diseases has led to an urgent search for candidate cellu-
lar mechanisms for therapeutic intervention. Protein
turnover has long been implicated in many of the most
common neurodegenerative diseases, through the dis-
covery that several proteins genetically linked to familial
forms of disorders form stable aggregates within cells.
Well-described examples include AD associated amyloid
plaques and hyperphosphorylated Tau containing neuro-
fibrillary tangles, PD associated Lewy bodies and neur-
ites, and cytosolic inclusions of Amyotrophic Lateral
Sclerosis (ALS). The accumulation of these mono- and
oligomeric peptides suggests ineffective cellular clear-
ance of macromolecules, in particular via the endo-
lysosomal and autophagic machinery. Emerging genetic
and molecular biological evidence now suggests that
both systems may be dysfunctional across a broad
spectrum of neurodegenerative disorders, their contribu-
tion expanding beyond just the turnover of aggregation
prone proteins in neurons (Table 1). Here we summarilyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Neurodegenerative disease associated gene associated with autophagy and endo-lysosomal processes
Gene Process Evidence Key References
Alzheimer’s Disease
APOE Early endosomes GA [2]
BECN1 Macroautophagy BM [3–5]
BIN1 Early endosomes GA [6]
CD2AP Early endosomes GA [7]
CLU Early endosomes GA [8, 9]
EPHA1 Early endosomes GA [10, 11]
PICALM Early endosomes GA [8]
PSEN1 Recycling endosomes / Lysosomes GA [12]
RAB7A Mitophagy / Late endosomes BM [13]
SORCS1 Retromer GA [14]
SORL1 Early endosomes / Retromer GA [14]
Parkinson’s Disease
DNAJC6 Early endosomes / Retromer GA [15, 16]
FBXO7 Mitophagy CM [17, 18]
GAK Late endosomes GA [19]
GBA Mitophagy, Lysosome GA [20]
LRRK2 Mitophagy / Macroautophagy / Chaperone-mediated mitophagy (CMA) CM [21–23]
PINK1 Mitophagy CM [24, 25]
PRKN Mitophagy CM [26, 27]
RAB29/RAB7L1 Late endosomes GA [28]
SNCA Macroautophagy CM/BM [29]
SYNJ Early Endosomes GA [30, 31]
UCH-L1 CMA GA/BM [32, 33]
VPS35 Retromer CM [34, 35]
Huntington’s Disease
ATG7 Macroautophagy GA [36, 37]
BECN1 Macroautophagy BM [38]
HTT Early endosomes / Recycling endosomes CM / BM [39, 40]
Amytrophic Lateral Sclerosis / Frontotemporal Dementia
CHMP2B Early Endosomes GA / CM [41, 42]
OPTN Macroautophagy / Mitophagy GA [43]
p62/SQSTM1 Macroautophagy CM [44, 45]
TBK1 Macroautophagy / Mitophagy CM [46, 47]
Charcot Marie Tooth
RAB7A Mitophagy / Late endosomes CM [48]
SH3TC2 Recycling endosomes CM [49]
Niemann-Pick Disease
NPC1 Lysosomes CM [50, 51]
NPC2 Lysosomes CM [52, 53]
BM Biomarker: genes with histological, molecular or biochemical evidence for contribution of gene in neurodegenerative disease; CM Causative Mutation: Genes
associated with hereditary forms of neurodegenerative disease; GA Genetic Association: Genes where association with neurodegenerative disease has been made
through -omics research
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tophagy dysfunction in progressive neurodegenerative
disorders, using specific examples of their contribution
from common disorders to illustrate key concepts.Autophagy
Autophagy is a process of ‘self-eating’ through which
unwanted or toxic macromolecules and organelles are
sequestered and delivered to the lysosome to generate
raw materials including proteins, lipids, carbohydrates
and nucleic acids for use in metabolic processes. In
most cell types, autophagy functions primarily in re-
sponse to starvation [54] and some forms of apoptosis
[55]. However, in post-mitotic neurons, where the
programmed death and replacement of unhealthy cells
is not a viable option, autophagy takes on a more
crucial role in maintaining normal cellular homeosta-
sis, in particular the critical turnover of misfolded
proteins and damaged organelles. This is demon-
strated by observations of increased autophagy in re-
sponse to acute brain damage such as strokes and
traumatic brain injuries, however there is still contro-
versy as to whether this response is homeostatic or
pathological (reviewed by [56]). There are three
mechanistically distinct forms of autophagy that func-
tion within neurons; macroautophagy, chaperone-me-
diated autophagy (CMA) and microautophagy, each of
which have been implicated in maintaining normal
neuronal function or in neurodegeneration.Fig. 1 Autophagy and endo-lysosomal mechanisms and related genes asso
formation of an isolation membrane to engulf cargos selected for degrada
double membrane autophagosome marking the final step before lysosoma
molecules for either recycling or targeting to the lysosome, with chaperon
cargos to the lysosomes. Hydrolytic enzymes within the acidic lysosomal lu
released into the cellular cytoplasm. Neurodegenerative disease causing or
alongside the process in which they are involved. For additional informatioMacroautophagy signalling cascade
During macroautophagy, macromolecules and organelles
such as mitochondria and peroxisomes are sequestered
within specialised vesicles and digested for removal or
generation of raw material (Fig. 1). Macroautophagy is a
complex sequential process composed of multiple steps
which are generally considered consistent between cell
types, predominantly facilitated by a cascade of Autoph-
agy Related Genes (ATG). Sensing is the crucial first
step in autophagy induction, where the cell makes a
choice to induce degradation of toxic or superfluous cel-
lular components. In normal healthy physiological con-
ditions, the serine-threonine kinase mammalian target of
Rapamycin (mTOR), the master sensor for autophagy,
forms the mTOR complex (MTORC1) to promote cell
growth [57]. Depleted levels of cellular cyclic adenosine
monophosphate (cAMP) activate 5′-adenosine mono-
phosphate activated protein kinase (AMPK), which in
turn phosphorylates unc-51 like autophagy activating
kinase 1 (ULK1), promoting it to form a complex with
Focal Adhesion Kinase Family Kinase-Interacting protein
Of 200 KDa (FIP200), ATG13 and ATG101 [58, 59]. Ini-
tiation/nucleation triggers formation of the ‘phagophore’,
a lipid double membrane produced to encapsulate the
target cargo, restricting it to a smaller cytoplasmic re-
gion for further processing. To enable phagophore for-
mation, ULK1 phosphorylates and activates the vacuolar
protein sorting 34 (VPS34) complex, consisting of the
class III phosphatidylinositol-3-kinase VPS34, Beclin1,
VPS14 and VPS15 [60]. The activated VPS34 complexciated with neurodegenerative diseases. Macroautophagy begins with
tion. Elongation of the isolation membrane results in formation of the
l fusion and degradation. In parallel the endosomal system sorts
e-mediated autophagy (CMA) and microautophagy also delivering
men digest the target and the constituents resulted from this are
associated genes affecting various stages of autophagy are listed
n relating to disease association of listed genes, refer to Table 1
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phatidylinositol 3-phosphate (PI(3)P), recruiting add-
itional autophagy machinery. The phagophore next
undergoes elongation, facilitated by two processes.
Firstly, phosphatidylethanolamine is covalently bound to
cytosolic Microtubule Associated Protein 1 Light Chain
3 and GABARAP family proteins (herein LC3-I), produ-
cing an autophagosome-associated LC3-II [61]. Secondly
a complex of ATG5-ATG12-ATG16 associates with the
isolation membrane, allowing it to entirely enclose the
whole target organelle [62]. Selection of cargos occurs in
parallel to sensing, initiation and elongation, marking
substrates for autophagy. Proteins are targeted for au-
tophagy by ubiquitination and labelling primarily with
p62/Sequestosome-1 (p62), which through an ATG8
interaction motif/LC3 interacting region (AIM/LIR) [63,
64] recruits LC3-II to the isolation membrane [65].
Other cargo recognition proteins including Neighbour
Of BRCA1 Gene 1 (NBR1), Nuclear Domain 10 Protein
52/ Calcium Binding And Coiled-Coil Domain 2
(NDP52), and Optineurin (OPTN), also contribute to
specific targets for autophagy [66]. Once target cargos
are bound by LC3-II, further initiation machinery is re-
cruited. Closure of the membrane leads to formation of
a double membraned vesicle called an ‘autophagosome’,
containing the target cargos. Since their formation can
occur in synapses and neurites significant distances from
the neuronal soma [67], transport of autophagosomes is
often necessary for their delivery to appropriate cellular
compartments for degradation. Autophagosomes finally
undergo fusion with late-endosomes or lysosomes to de-
liver substrates for hydrolytic enzymatic degradation.
Macroautophagy
Macroautophagy is a highly conserved process [68, 69]
and unsurprisingly several key molecules and mecha-
nisms are associated with neuronal dysfunction and de-
generative conditions. The critical importance of
autophagy in neuronal health is best documented in
model organisms deficient for genes required for the ini-
tial steps of autophagy. The ULK1 homologue, serine/
threonine-protein kinase unc-51 was first identified in a
C. elegans screen for genes associated with ‘uncoordin-
ated’ phenotypes, with its dysfunction resulting in in-
complete developmental axon outgrowth and elongation
[70], clearly demonstrating the importance of autophagy
in normal neurodevelopment. Current research however,
also suggests that aberrant autophagy plays a fundamen-
tal role in ageing and neurodegeneration. Conditional
deletion of essential autophagy genes in mice has dem-
onstrated the critical requirement for neuronal autoph-
agy in adult animals. Mice lacking neuronal expression
of the autophagosome membrane elongation genes
ATG5 [71] or ATG7 [72] are viable into adulthood,however they show significantly reduced autophagy, as-
sociated with progressive motor dysfunction and neuro-
degeneration. A notable observation from both ATG5
and ATG7 deletion models was the formation of intra-
neuronal inclusion bodies composed of ubiquitinated
protein. Large protein aggregates are considered a hall-
mark histopathological feature of many neurodegenera-
tive disorders, though their precise contribution (or even
protection) is poorly defined.
Genetic evidence from several neurodegenerative dis-
eases supports a contribution for protein accumulation
in pathogenesis, with hereditary mutations in many ag-
gregation prone proteins, and also dysfunction of cargo
selection genes required for targeting inclusions to the
autophagy system. Natively unfolded alpha-synuclein
[29] forms Lewy bodies and neurites in PD and associ-
ated Parkinsonisms [73], with hereditary point mutations
increasing aggregation propensity [74]. Hyperphosphory-
lation of Microtubule Associated Protein Tau (Tau) ac-
cumulates in neurofibrillary tangles [75–77] in several
neurodegenerative diseases including AD and familial
forms of Frontotemporal Dementia (FTD) [78]. Extracel-
lular amyloid beta (Aβ) plaques are a hallmark of AD,
composed of fragments of amyloid precursor protein
(APP) [79, 80] generated by presenilin secretases
(PSEN1/2) [81], with APP [82, 83] and PSEN genes [84,
85] mutated in familial AD. Both familial and sporadic
Amyotrophic Lateral Sclerosis (ALS) is associated with
cytosolic aggregation of proteins, most frequently TDP-
43 [86, 87], with FUS [88] and SOD1 [89–91] seen in
some familial cases. Mutations resulting in repeat expan-
sion are also associated with protein aggregation such as
the ALS/FTD linked gene C9ORF72 [92–94], or polyglu-
tamine (polyQ) expansions seen in several disorders,
most prominently Huntingtin (HTT) in Huntington’s
Disease (HD) [39, 95]. Typically intracellular inclusion
bodies are ubiquitinated and labelled with autophagy re-
ceptor proteins, most commonly p62 [96], suggesting
autophagy plays an active role in their clearance. Muta-
tions in p62 [44, 45] and OPTN [43] have been identified
in ALS and FTD, directly implicating effective protein
targeting for clearance in disease pathogenesis.
Mutations in core autophagy genes have not been
identified as directly causative in any common neurode-
generative disorders, though some rare conditions have
been reported [97]. There is however a wealth of data
implicating the mis-regulation of autophagy sensing and
initiation/nucleation in neurodegenerative disorders,
particularly HD. Experiments in cellular [98], Drosophila
and mouse models of polyQ expanded HTT [99] have
demonstrated that promoting autophagy through
pharmacological inhibition of mTOR is sufficient to res-
cue phenotypes associated with HD toxicity. Contrasting
evidence suggests that expression of the mTOR
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RAS homolog enriched in the striatum (Rhes) can also
alleviate symptoms in HD mouse models [100], while
only transient protection is seen in R6/2 mouse treated
with mTOR inhibitors [101]. The contribution of au-
tophagy to HD is complicated by the fact that mTOR is
found within poly-Q rich protein aggregates [99] and
that polyQ-expanded HTT enhances mTORC1 activity
[102], suggesting a direct interaction of mTOR with
HTT. PolyQ-expanded HTT can disrupt nucleation of
the isolation membrane, by impairing the phosphoryl-
ation of Beclin-1 associated ATG14 and VPS34 complex
activity [103]. Pro-nucleation has also been implicated in
polyQ-repeat associated Machado-Joseph disease/spino-
cerebellar ataxia type 3, with increased expression of the
VPS34 complex component Beclin-1 showing protective
activity in mouse models [104, 105]. Beclin-1 mediated
nucleation may also contribute to the pathology of AD.
In transgenic mouse AD models expressing human APP,
reduction of Beclin-1 expression leads to increased intra-
neuronal Aβ accumulation, extracellular Aβ deposition
and neurodegeneration [3]. Intriguingly, peptide frag-
ments produced through caspase cleavage of Beclin-1
have been detected in the brains of AD patients and
murine models, which exacerbated neurodegenerative
phenotypes when overexpressed [4]. Conversely,
caspase-resistant Beclin-1 was found to be neuroprotec-
tive, suggesting some post-translationally processed spe-
cies of Beclin-1 may themselves be toxic [4].
A direct function of ALS/FTD gene C9ORF72 in the
initiation of autophagy has also been suggested recently.
ALS/FTD can manifest through a 5′ hexanucleotide re-
peat expansion in the C9ORF72 gene, which can contain
several thousand repeats generating both RNAi and pro-
tein products that accumulate over time [92, 94]. In
addition to clear gain-of-function pathologies, mutant
C9ORF72 alleles may also reduce expression of some
isoforms of the gene, suggesting partial loss-of-function
may partially contribute to disease [92]. C9ORF72 has
been found to interact with RAB1A, a RAB GTPase ef-
fector molecule required for the recruitment of ULK1
complex to the phagophore [106]. Decreased levels of
autophagy have been reported in neurons derived from
C9ALS/FTD patients, and reduction of C9ORF72 ex-
pression in cultured neurons was found to attenuate au-
tophagy and accumulation of intracellular p62 puncta,
indicative of protein accumulation [106, 107].
Chaperone-mediated autophagy
Chaperone-mediated autophagy (CMA) is a selective
form of autophagy, whereby peptides carrying a KFERQ-
like motif are recognised by cytoplasmic chaperone pro-
teins, which then deliver the target directly to lysosomes
for degradation [108]. Target peptides are bound bycytoplasmic chaperones including Heat shock protein 90
(HSP90), delivered to the lysosome-associated mem-
brane protein 2A (LAMP2A) receptor on the lysosomal
membrane and transported into the lysosome lumen for
hydrolytic degradation. Unlike micro- and macroauto-
phagy, CMA is not evolutionarily conserved and has
only been observed in mammalian cells [109, 110].
CMA contributes to the clearance of proteins associ-
ated with several neurodegenerative disorders [111, 112],
with compelling evidence to suggest a role in the dopa-
minergic neuron loss seen in PD. Several genes genetic-
ally associated with familial forms of PD appear to
disrupt CMA. The natively unfolded alpha-synuclein
peptide is a substrate for CMA [113], however both sta-
bilised dopamine-bound peptides, [114] and PD-
associated mutant species [113] are ineffectively de-
graded through this process. Ubiquitin carboxyl-terminal
esterase L1 (UCHL-1), has been shown to interact with
heat shock protein 70 (HSC70), HSP90 and LAMP2A,
with disease associated mutations further increasing
binding and impeding CMA of alpha-synuclein [115].
PD-associated Leucine Rich Repeat Kinase 2 (LRRK2)
also appears to be degraded through CMA, with the PD
associated mutations rendering the protein a poor sub-
strate but also impeding the CMA translocation complex
[116]. Most recently, PD-associated deglycase DJ-1,
which functions in neuronal response to oxidative stress
and mitochondrial turnover, has also been found to
undergo CMA-mediated degradation, with a preference
for non-functional oxidised forms [117]. Reduced CMA
and turnover of non-functional DJ-1 was associated with
increased mitochondrial dysfunction and cell death in
repose to toxin induced oxidative stress [117]. CMA and
PD have also been associated through the degradation of
myocyte enhancer factor 2D (MEF2D), a transcription
factor that contributes to neuronal survival under stress
[118]. Inhibition of CMA through knockdown of HSC70
or LAMP2A results in accumulation of cytoplasmic
non-functional MEF2D in neuronal cultures, with in-
creased cytoplasmic MEF2D also reported in alpha-
synuclein transgenic mice and PD patient tissues [119].
Taken together, these findings suggest processing of PD-
associated peptides through CMA may be a contributing
factor in disease pathogenesis and progression and that
this process may be critical for the maintenance of dopa-
mine neurons in particular.
Microautophagy
Microautophagy is the least well characterised of the
three forms of autophagy, with its role in neurodegener-
ation mostly unexplored. In this process, proteins enter-
ing the endo-lysosomal system through invagination
are engulfed by the late endosome and lysosomal mem-
brane [120]. The synapse appears to be a particularly
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erative disorders, in part due to the constant turnover of
SNARE proteins required for neurotransmitter release,
which can form dysfunctional neurotoxic species [121].
Experiments in Drosophila have demonstrated that an
endosomal form of microautophagy can be perturbed
through knockdown of the synapse enriched chaperone
HSC70–4, required for recognition of the peptide deg-
radation motif, resulting in significantly perturbed
neurotransmitter release [122]. As microautophagy ap-
pears to support normal neuronal function, particularly
at sensitive synaptic terminals, further investigation
should be conducted in the context of neurodegenerative
disorders to define its contribution.
Selective autophagy
Autophagy mechanisms can also be subclassified into
those involving selective degradation of specific organ-
elles, such as peroxisomes (pexophagy), nuclei (nucleo-
phagy) and endoplasmic reticulum (ER-phagy), as well
as those involving degradation of molecular materials
such as lipids (lipophagy), stress granules (granulophagy)
and myelin (myelinophagy) (reviewed by [123]). Autoph-
agy receptors for selective targeting of organelles which,
under specific conditions, link these organelles with the
cellular autophagy machinery leading to their destruc-
tion, are being continuously discovered. Receptors im-
portant for pexophagy include NBR1 [124], Atg30 [125]
and Atg36 [126], whereas FAM134B [127] and Atg40
[128] are required for ER-phagy. Once bound to these
adaptors, cargos enter the autophagy cascade for lyso-
somal degradation.
Whilst the contribution of most cargo selective forms
of autophagy to neuronal health is largely unexplored,
mitophagy, perhaps the most thoroughly characterised,
has been strongly implicated in neurodegenerative dis-
ease. Mitophagy is the process by which dysfunctional
mitochondria are selectively targeted by autophagosomes
and degraded via autophagosome-lysosome fusion, facili-
tating a quality-control mechanism which maintains a
healthy mitochondrial network (Fig. 2). Due to their high
metabolic demand and post-mitotic state, neurons are
particularly sensitive to mitochondrial dysfunction and
thus mitophagy is vitally important in this cell type. Like
other forms of selective autophagy, the targeting of
mitochondria for mitophagy occurs though a mechanism
which parallels that of general macroautophagy cargo
targeting, but with specific adapters that allow for the se-
lective targeting of damaged organelles. The canonical
mitophagy model is that mitochondrial insult results in
the dissipation of mitochondrial membrane potential
(ΔΨm), followed by a block of PTEN-induced kinase 1
(PINK1) import into the intermembrane space, where it
is usually cleaved by Presenilin Associated Rhomboid-Like (PARL) [129]. PINK1 accumulates on the mito-
chondrial outer membrane (MOM) and phosphorylates
ubiquitin at Ser65 (pS65-Ub), leading to the recruitment
of Parkin E3 Ubiquitin Protein Ligase (PRKN) from the
cytosol [130]. PINK1 also phosphorylates PRKN at Ser65
of its ubiquitin-like domain, stimulating PRKN E3 ubi-
quitin ligase activity [131]. This triggers a positive-
feedback mechanism during which subsequent PRKN re-
cruitment and ubiquitination of MOM proteins [132,
133] results in the recruitment of AIM/LIR autophagy
adapters including p62, OPTN and TAX1 Binding Pro-
tein 1 (TAX1BP1). The kinase domain of PINK1 has
been shown to recruit OPTN and NDP52 independent
of PRKN and recruitment of these two adapters is essen-
tial for mitophagy [134]. Though responsible for recruit-
ing LC3-II to the poly-ubiquitinated MOM [135], p62 is
dispensable [134, 136] but can improve the efficiency of
mitochondrial incorporation into autophagosomes at a
later stage in the process. The ULK1 complex transiently
assembles at depolarised mitochondria [137], in a
PRKN-dependant, LC3-II-independent fashion. ATG9A
vesicles are also recruited / formed de novo at depo-
larised mitochondria, independently of ULK1 recruit-
ment. ULK1 and ATG9A foci only partially co-localise
at mitochondria and neither are required for the recruit-
ment of LC3-II, though both are required for mitophagy
to occur [137].
The most well-established association between defect-
ive mitophagy and neurodegeneration is with PD since
PRKN was discovered as the causation of autosomal-
recessive juvenile parkinsonism (ARJP) in a Japanese
population [26, 27] and PINK1 was subsequently identi-
fied as a second ARJP associated gene [24, 25]. Initial
functional characterisation of both genes was performed
in Drosophila, demonstrating loss of function mutations
in the Drosophila PRKN homologue parkin cause aber-
rant mitochondrial morphology in energy demanding
cell types, such as sperm, flight muscle and, more rele-
vant to PD, dopaminergic neurons [138, 139]. Similar
phenotypes were observed in Pink1 mutant Drosophila
and genetic epistasis experiments showed that overex-
pression of parkin rescued Pink1 mutant phenotypes but
not vice versa, placing PRKN downstream of PINK1 in a
common pathway of mitochondrial quality control
[140–142]. PINK1 and PRKN patients feature the loss of
DA neurons of the substantia nigra pars compacta and
mitochondria are enlarged in induced pluripotent stem
cells (iPSC)-derived DA neurons from these patients
[143]. Taken together, PINK1 and PRKN genetic and ex-
perimental evidence strongly associate loss of normal
mitophagy with ARJP.
Histopathological post-mortem analysis of PD pa-
tient brains also suggests disrupted turnover of mito-
chondria. Mitochondrial complex I defects in the
Fig. 2 Mitophagy and related genes associated with neurodegenerative diseases. Dysfunctional mitochondria are targeted for autophagic
clearance by a number of specific adapters which are associated with neurodegenerative disorders. Upon depolarisation, PTEN-induced kinase 1
(PINK1) accumulates on the mitochondrial outer membrane (MOM), where it phosphorylates Ser65 of ubiquitin and the ubiquitin-like domain of
PRKN. pS65-Ub acts as a positive-feedback mechanism for the further recruitment of PRKN to the MOM and activation of its E3 ubiquitin-ligase
activity. PRKN ubiquitinates a number of targets on the MOM, including mitochondrial fusion proteins such as Mitofusin1 (MFN1), decorating the
damaged organelle in poly-ubiquitin chains. F-Box Only Protein 7 (FBXO7) also participates in MFN1 ubiquitination. PINK1, PRKN and pS65-Ub
chains on the MOM facilitates the recruitment of autophagy adapters Phosphotyrosine-Independent Ligand For The Lck SH2 Domain Of 62 KDa
(p62), Nuclear Domain 10 Protein 52 (NDP52) and Optinuerin (OPTN). Parkinson’s disease-associated mutations in β-glucocerebrosidase (GBA) and
Leucine Rich Repeat Kinase 2 (LRRK2) are considered to impair PRKN-mediated mitophagy. Phosphorylation of ALS-associated TBK1 in response to
mitochondrial damage is dependent on NDP52 and OPTN recruitment, but subsequently increases the affinity of OPTN for poly-ubiquitin on the
MOM. TBK1 also phosphorylates RAB7A, which in turn facilitates the recruitment / formation of ATG9 vesicles. The ULK1 complex and ATG9
vesicles are recruited / form de novo at damaged mitochondria and initiate autophagic engulfment. This is enhanced by the recruitment of LC3-
II by p62. Neurodegenerative disease causing or associated genes affecting various stages of mitophagy are listed. For additional information
relating to disease association of listed genes, refer to Table 1
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pathology [144], indicating that deficient mitochon-
drial quality control is a common feature across fa-
milial and sporadic cases of PD (reviewed [145]). A
signature of damaged mitochondria, polymeric pS65-
Ub, accumulates in cytoplasmic granules, beaded
neurites and granulovacuolar degeneration bodies with
age in healthy individuals [146, 147]. In sporadic PD
and Dementia with Lewy Bodies patients, these struc-
tures have been identified in the proximity of Lewy
bodies. Their abundance positively correlates with
both age and Braak stage, demonstrating age and
disease-associated increases in mitochondrial quality
control [147]. Expectedly, given that PINK1 and
PRKN are responsible for generating pS65-Ub chains
on the MOM, pS65-Ub positive structures are mark-
edly reduced in PINK1 and PRKN post-mortembrains, inferring that defects in mitophagy are ob-
served in these patients [146, 147].
Mitophagy-related roles can further be attributed to
several other PD-associated genes. Mutations in another
E3 ubiquitin ligase, F-Box Only Protein 7 (FBXO7), were
identified as the cause of parkinsonian pyramidal syn-
drome, a rare form of ARJP which presents with pyram-
idal tract dysfunction [17, 18]. FBXO7 enhances PRKN
recruitment to depolarised mitochondria and also partic-
ipates in the ubiquitination of Mitofusin 1 (MFN1), fa-
cilitating the segregation of damaged mitochondria from
the healthy mitochondrial network [148]. The most fre-
quent cause of autosomal dominant PD is the G2019S
hypermorphic variant of LRRK2. Cold-shock induced
mitophagy is impaired in fibroblasts derived from pa-
tients with either PRKN mutations or the G2019S
LRRK2 variant. This effect is reversed by treatment with
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PRKN loss-of-function fibroblasts [149]. LRRK2-in-1
may also protect against oxidative stress by restoring
basal mitophagy levels in a subset of sporadic PD de-
rived fibroblasts [150].
Mitophagy has more recently been implicated in other
neurodegenerative diseases. PINK1 has been identified in
GWAS of genetic modifiers of HD progression, along
with a number of regulators of mitochondrial fission/fu-
sion dynamics [151]. In a Drosophila model of HD,
Pink1 overexpression rescues mitochondrial morph-
ology, conveys neuroprotection and extends lifespan, in-
dicating that defects in mitophagy may also contribute
to aspects of HD pathogenesis [152]. ALS-associated
mutations in OPTN or TANK-binding protein 1 (TBK1)
block efficient clearance of depolarised mitochondria in
PRKN-expressing HeLa cells, indicating that both of
these proteins are important, though not essential, in
mitophagy [153]. TBK1 is rapidly phosphorylated and
activated upon mitochondrial damage and this is
dependent on the mitochondrial recruitment of NDP52
and the ubiquitin binding domain of OPTN. In turn, p-
TBK1 phosphorylates OPTN, enhancing its affinity for
polyubiquitin and thus its retention at depolarised mito-
chondria [154]. p-TBK1 also phosphorylates RAB7A
[155] required for ATG9-vesicle formation and efficient
mitophagy in PRKN-expressing HeLa cells [155–157].
Some ALS-associated missense mutations in TBK1 abol-
ish its phosphorylation, activation and ability to phos-
phorylate OPTN [158], thus defects in mitophagy could
play a role in the pathogenesis of patients with these
mutations.
Changes in mitophagy may also occur in diseases
where genetic evidence does not clearly suggest a mito-
chondrial contribution to pathology. In AD, post-
mortem hippocampal tissues exhibit strikingly lower
levels of mitophagy, assessed by mitochondria-lysosome
co-localisation and visualisation of mitophagy events by
transmission electron microscopy. These deficits correl-
ate with decreased PINK1, p-TBK1 and p-ULK1 in the
same samples and also in iPSCs derived from apolipo-
protein E4 (APOE4) and APP-mutation carrying patients
[159]. Furthermore, there is evidence that upregulation
of mitophagy may protect against AD phenotypes. Uro-
lithin A (UA), a metabolite produced in the gut from the
ellagitannin class of polyphenols found in pomegranate,
raspberries and walnuts, upregulated mitophagy in nem-
atodes and rodents in a manner dependant on PINK1/
PRKN and independent of general macroautophagy
[159, 160]. UA treatment ameliorated learning and
memory defects in both Aß and hyperphosphorylated
Tau in a C. elegans models, and improved cognition in
mouse models of AD [159]. Intriguingly this study found
microglial activation and neuroinflammation werereduced upon UA treatment in APP-PSEN1 mice, sug-
gesting mitophagy deficits are tied to chronic inflamma-
tion in the brain, a hallmark of many neurodegenerative
diseases. The anti-inflammatory cytokine Interleukin 10
was increased in hippocampal microglia of these mice
upon UA treatment, in a PINK1-dependent fashion, in-
dicating that this anti-inflammatory response is also
likely dependent on mitophagy. Interleukin 10 has previ-
ously been shown to promote mitophagy through inhib-
ition of the mTOR pathway in lipopolysaccharide-
activated macrophages, maintaining a healthy mitochon-
drial network and a metabolic profile based on oxidative
phosphorylation as opposed to glycolysis [161]. Micro-
glial activation is associated with a respiratory switch
from oxidative phosphorylation to glycolysis, facilitated
by the glucose transporter GLUT1. The GLUT1-specific
inhibitor STF31 supresses neuroinflammation and neu-
rodegeneration in a mouse model of light-induced ret-
inal degeneration [162]. These studies thus identify a
promising strategy for combatting both mitochondrial
dysfunction and chronic neuroinflammation in neurode-
generative disease, through upregulation of mitophagy
and rebalancing of metabolic state.
Therapeutic targeting of autophagy in
neurodegeneration
Through their implication in a broad range of neurode-
generative disorders, endo-lysosomal and autophagy
mechanisms have become appealing targets for thera-
peutic intervention [163]. Autophagy targeting com-
pounds fall in two broad categories, acting through
mTOR-dependent or -independent mechanisms. Modu-
lation of mTOR-dependent autophagy via inhibition of
mTORC1 with rapamycin has been widely explored
across a spectrum of human diseases, including various
forms of cancers, auto-immune and neurodegenerative
disorders [164]. Rapamycin possesses strong immuno-
suppressant and anti-proliferation properties which,
though beneficial for treatment of cancer and auto-
immune disorders, are undesirable for chronic treatment
of neurodegenerative disorders. As rapamycin has been
found beneficial in treatment of neurodegeneration in
preclinical models [165], attempts to circumvent its im-
munosuppressant activity have been made through
“Rapalog” derivative molecules, several of which have
been demonstrated to improve phenotypes in models of
neurodegenerative disorders including HD [99], spino-
cerebellar ataxia type-3 [166] and FTD-associated tauo-
pathy [167].
Several mTOR-independent modifiers of autophagy
are gaining interest as therapeutics, with AMPK activat-
ing molecules such as trehalose and metformin proving
effective in reducing neurodegenerative phenotypes in
models of AD [168, 169], ALS [170–172], HD [173, 174]
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ciated with the core autophagy machinery have also been
found to modify neurodegeneration, including Estrogen
Related Receptor α [176] and cAMP [177, 178]. Interest-
ingly, the widely used AD-therapeutic memantine has
emerged from a screen of clinically approved molecules
which enhance autophagy [179], suggesting a potential
mode of action for the drug which may be repurposed in
other neurodegenerative disorders.
Endosomes
Endosomes capture surface molecules through internal-
isation of the plasma membrane, or acquire cargo intra-
cellularly following trans-golgi trafficking. Multiple
checkpoints along the endosomal pathway either desig-
nate cargos for degradation at the lysosome or recycle
them back to the plasma membrane or golgi via the ret-
romer complex [180, 181]. Endosomes exist in three spe-
cific states: early (also called sorting), recycling, or late
depending on their post internalisation stage and associ-
ation with distinct Rab guanosine triphophatases (RAB
GTPases) [182].
Early endosome
The early endosome (EE) serves as the primary sorting
compartment of the endocytic pathway, receiving extra-
cellular material, lipid membranes and membrane-
bound proteins from small endocytic vesicles, formed
from specialised clathrin-coated invaginations of the
plasma membrane. Upon their delivery to the EE, cargos
are separated within minutes and assigned for either
degradation or recycling. Proteins destined for recycling
back to the plasma membrane first cluster within tubular
EE extension membranes, whereas the larger and
rounder EE compartment houses proteins targeted for
degradation. Retrograde transport of cargos from the EE
to the trans-golgi network is facilitated by the Retromer
complex, which consists of VPS26-VPS29-VPS36 cargo
recognition and sorting nexin (SNX) membrane recogni-
tion components [183]. Endosomal cargo separation is
regulated primarily by RAB4 [184] and RAB5 [185], in
addition to some other less well characterised GTPases
including RAB10 [186], RAB14 [187], RAB21 [188] and
RAB22 [189]. These RAB proteins facilitate either the re-
cruitment of additional RABs to enable vesicle matur-
ation or provide a platform for other proteins and
protein complexes to dissociate and re-associate with
the vesicle membrane [190] for trafficking or sorting
purposes. The PI(3)P rich EE membrane itself is also
generated through recruitment of PI 3-kinase VPS34 by
RAB5 [191].
Initial endocytosis is disturbed in several age-
dependent neurological disorders, notably PD where
mutations have been identified in several EE genes. Thesynaptic enriched inositol-phosphatase Synaptojanin 1
(SYNJ1) binds clathrin and associated proteins, likely
contributing to the uncoating of clathrin coated vesicles.
Loss of SYNJ1 is associated with dysfunctional endocyto-
sis [192, 193], through disruption of the earliest stages of
EE formation [30, 31]. Indeed, enlarged EEs and altered
trafficking have been seen in fibroblasts derived from
early onset PD patients carrying SYNJ mutations [194].
Endocytosis in PD may further be perturbed by disrup-
tion of DnaJ/Heat Shock Protein Family (HSP40) co-
chaperone (DNAJC) proteins [195], notably DNAJC6/
Auxilin-1 and DNAJC13/RME-8. Neuron-specific
DNAJC6/Auxilin-1 interacts with HSC70, facilitating the
uncoating of clathrin vesicles [15, 196], whilst
DNAJC13/RME-8 decreases retromer-mediated cargo
transport sorting through interaction with SNX1 thereby
preventing the formation of the necessary tubular struc-
ture of the EE membrane [197, 198]. Disruption of retro-
mer activity has also been directly implicated in PD
through mutations in the retromer complex gene VPS35
[34, 35]. PD-associated mutations in LRRK2 have also
recently been found to alter expression of essential
endocytic proteins and also impair endocytosis of
clathrin-associated synaptic vesicles in patient derived
dopaminergic neuron cultures [199]. Lipophilic and ag-
gregation prone alpha-synuclein may itself inhibit retro-
mer recycling of some membrane proteins through
blocking VPS17 and SNX3 from EE association [200].
Beyond PD, several other neurodegenerative disorders
have been linked to the EE system. RAB5 interacts with
Early Endosome Antigen 1 (EEA1), a soluble N-
ethylmaleimide-sensitive fusion protein attachment pro-
tein receptors (SNARE) complex interacting protein, to
enable vesicle fusion [191] and recruitment of HTT via
HTT associated protein 40 (HAP40) to enable endosome
motility [201]. The poly-Q repeat expansion found in
disease associated alleles of the HTT gene has been
found to upregulate HAP40, facilitating a shift of EEs
from microtubules to actin thereby decreasing trafficking
speeds [39, 40]. EE dysfunction may also contribute to
juvenile-onset ALS through mutations to Alsin Rho
Guanine Nucleotide Exchange Factor (ALS2) [202, 203].
ALS2 contains several domains required for guanine-
nucleotide exchange required for RAB activation. Loss-
of-function mutations in the ALS2 gene have been found
to interfere with GDP/GTP exchange required by RAB5
[204], resulting in EE accumulation and trafficking ab-
normalities [205]. EE function has long been of interest
in AD pathogenesis, initially due to enlargement of
RAB5 positive vesicles being one of the earliest patho-
logical events seen in patient tissue [206]. This is not
surprising given that the EE pathway is compromised at
many levels from the endocytosis of secretases residing
on the plasma membrane, intracellular trafficking of key
Malik et al. Molecular Brain          (2019) 12:100 Page 10 of 21enzymes through the internalisation of extracellular
Aβ. More recently, emerging evidence suggests that
genes associated with an increased risk for developing
late-onset sporadic AD may converge on microglia
[207], with several endocytic genes potentially con-
tributing to pathology. Proteins encoded by AD risk
genes, including Bridging Integrator 1 (BIN1) [6],
CD2AP, EPHA1 [10, 11], PICALM [8], Sortilin Related
Receptor 1 (SORL1) [14], amongst others [7, 208, 209]
may all interfere with EE function. SNPs in BIN1 rep-
resent one of the most common AD risk associated
mutations after APOE. RAS and RAB interactor 1
(RIN1), a BIN1 interacting protein, functions as guan-
ine nucleotide exchange factor (GEF) for the RAB5
GTPase family. This interaction was found to pro-
mote epidermal growth factor receptor (EGFR) down-
regulation [210]. SNPs associated with BIN1 are also
likely to affect other critical RAB5 dependent pro-
cesses, which require further investigation.
Retromer-mediated sorting from the EE further con-
trols intracellular shuttling proteins relevant to AD in-
cluding APP and Beta-Secretase 1 (BACE1), which are
required to generate Aβ [211]. Knockout of retromer as-
sociated Vps35 in a mouse model of AD enhanced levels
of amyloidogenic Aβ species [212], suggesting that retro-
mer signalling from the EE is a negative regulator of Aβ
production. This theory is bolstered by genetic evidence
linking SNPs and gene expression of Sortilin Related
VPS10 Domain Containing Receptor 1 (SORCS1) [213], a
membrane homologue of SORL1, to impaired retromer-
associated sorting which may lead to APP processing
deficits [214]. SNPs in APOE [215] and Clusterin may
also accelerate extracellular Aβ-uptake and clearance
[216, 217] decreasing endocytosis capacity later in dis-
ease. Given the role of EE dysfunction in a diverse range
of neurological disorders, this pathway may represent a
common mechanism of either disease manifestation or
disease progression.
Recycling endosome
Portions of neuronal plasma membrane and residing
surface receptors that have been internalised and lost
through EE formation are replenished by recycling
endosomes (REs). At the ultrastructural level, REs
have a tubular formation and form a non-continuous
network [218], identified in tissues through associ-
ation with RAB11 [219]. Lipids to be recycled are
sorted away from those ubiquitylated receptors and li-
gands that are destined for degradation due to the
REs acidic environment (pH ∼ 6.0) [220]. Endosomal
recycling can be rapid, occurring within 2–3 min or
can take around 10 mins from initial endocytosis. Dif-
ferent RAB subtypes appear to be required for either
fast or slow kinetics, with RAB35 associated with fastmoving vesicles and RAB11 slow [221–223], although
why these different mechanisms exist and under what
cellular conditions they occur is not well understood.
Although the RE compartment is relatively understud-
ied compared to EE, several links to neurodegenerative
diseases have been made. The activity of recycling endo-
some associated RAB11 is at least in part controlled
through interaction with HTT. The removal of GDP
from RAB11 is compromised by mutant polyQ expanded
HTT in human cells, leading to deficits in RE size and
receptor recycling [224], impacting dendritic spine com-
plexity in rodent models and patients [225] and electro-
physiology, lifespan and locomotion in Drosophila
models of HD [225, 226]. RAB11 and its role in regulat-
ing recycling endosome activity has been implicated in
disease beyond HD. Charcot-Marie-Tooth peripheral
neuropathy type 4C associated SH3 domain and tetratri-
copeptide repeats 2 (SH3TC2) [49] is considered a
RAB11 effector protein, localising to GTP-bound species
[227]. In CMT4C, mislocalisation of SH3TC2 and lack
of RE trafficking is considered a causative feature of dis-
ease progression [227]. Increasingly targeting RAB11 ac-
tivity is now considered a keen therapeutic target for
HD, with potential benefits for other neurodegenerative
diseases.
Another important molecule bound to the EE/RE
following secretion from the golgi is the gamma-
secretase component PSEN1. Although enhanced
amyloidogenic Aβ production is likely to play a role in
disease manifestation, a recent report also suggests
that it is the accumulation of β C-terminal fragments
which cause RE dysfunction [228]. In this model, mu-
tant forms of PSEN1 and APP decrease RAB11
dependent trafficking from the cell body to the axon
[228]. Hence neurons have a decreased capacity to de-
liver lipoproteins, receptors and transporters back to
the plasma membrane in vulnerable sub-
compartments. Lysosome restricted PSEN2, which also
cleaves APP, may play a more important role in nor-
mal cellular Aβ production, with more toxic species
generated by the mislocalisation of mutant PSEN1
from the EE/RE to the lysosome [229].
Genetic evidence indicates that recycling of specific
proteins confers neurodegenerative disease specificity.
However, general RE disruption may contribute to
neuronal demise indirectly. Several substrates of the
RE pathway suggest why its disruption is so clearly
detrimental to neuronal function. RAB11 vesicles have
been found to carry important neurotrophic factors,
such as BDNF [230] and critical synaptic receptors,
such as AMPA [231]. Although loss of recycling cap-
acity may not initially drive cell death, it may be key
to understanding why synapses are preferentially lost
early in disease.
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Late endosomes (LEs) / multi-vesicular bodies (MVBs)
are generated through the maturation of EEs. Endosomal
Sorting Complex Required for Transport (ESCRT) com-
plexes 0-III and several VPS proteins are also recruited
to ubiquitinated surface molecules on the cytosol facing
endosomal membrane. ESCRT complexes facilitate the
invagination of endosome membrane proteins and lipids,
producing a MVB, an endosome containing smaller
intraluminal vesicles [232]. During this maturation
process RAB5 and RAB4 dissociate from the endocytic
membrane and RAB7 and RAB9 are recruited. Genetic
and cell biological evidence suggest that adequate RAB7
function to initiate clearance through LE-lysosomes fu-
sions may be a critical factor in maintaining normal
neuronal function [233]. RAB7 can also assist the re-
cruitment of the retromer to late endosomes through
interaction with VPS35 [234]. LEs/MVBs acidify to pH
levels of 6.0–4.9 [235] in the final step of the endocytic
pathway before intraluminal cargos are delivered to the
lysosome for degradation (discussed below).
Dysfunction of LE activity in neurodegenerative ap-
pears mostly restricted to PD, spearheaded by genetic as-
sociation. GWAS approaches have identified LRRK2
mutations as common risk factors for the development
of sporadic PD [21, 22], in addition to mutations in Cyc-
lin G Associated Kinase (GAK) and the LE associate
RAB7L1 [19, 236]. Highlighting the importance of the
LE pathway in the maintenance of the large highly
arborised dopamine neurons, a protein complex of
LRRK2, RAB7 and GAK was previous uncovered by an
unbiased protein-protein interaction experiment [237].
Overexpression of these molecules promotes protein
clearance from the trans-Golgi network, suggesting that
trafficking from golgi to LE is compromised in PD.
LRRK2 was also found to impede cargo trafficking by
prohibiting budding of the LE membrane to form
smaller vesicles, via decreased RAB7 activity [238], a
process exacerbated by PD associated mutations. LRRK2
kinase inhibition via small molecules increases lysosome
formation [150], suggesting that LE dysregulation dir-
ectly impacts on clearance. Loss of LRRK2 or RAB7 also
downregulates VSP35 [239] which may further perpetu-
ate the dysregulation of the endosomal pathway up-
stream of the LE. The ESCRT-III complex has also been
implicated in neurodegeneration through its function to
concentrate endosomal cargos into LE intralumenal vesi-
cles. ALS/FTD associated charged multi-vesicular body
protein 2B (CHMP2B) mutations [41, 42] were found to
cause severe lysosome pathologies [240] and metabolic
disturbances in neurons [241]. This evidence shows that
LE perturbations may therefore lead to downstream
lysosome-mediated clearance complications or initiate
dysfunction in earlier in the endocytic pathway.Lysosomes
Lysosomes are the terminal compartment through which
macromolecules are degraded and recycled to generate
nutrients. Lysosomes are generated through the matur-
ation of LEs, achieved via delivery of hydrolytic enzymes
from the golgi and also active acidification of the lumen
via the lysosomal vATPase hydrogen pump. Once acid-
ified to approximately pH 5, over 50 hydrolytic enzymes,
including a broad range of glycosidases and proteases
degrade the contents. The matured lysosome is able to
fuse with and degrade the contents of other vesicular
compartments including endosomes, autophagosomes,
amphisomes (fused endosome-autophagosome) and pha-
gosomes (phagocytosed material). A wide range of cellu-
lar macromolecules can be processed through the
lysosome, including nucleic acids, proteins, carbohy-
drates and lipids. Several aspects of lysosomal biology in-
cluding enzymatic dysfunction and positioning have
been implicated in neurodegenerative disorders.
Lysosome function
As lysosomal degradation is one of the primary mecha-
nisms of cellular waste removal, it is unsurprising that
genes facilitating this essential process have been linked
to a broad range of diseases. Lysosomal Storage Disor-
ders (LSD) are a family of hereditary conditions in which
substrates of lysosomal degradation accumulate within
the lumen, caused by mutations in a range of lysosome
specific hydrolases, enzymatic regulators, membrane
proteins and transporters. Many of the > 50 genes linked
to LSDs cause juvenile neurodegenerative disorders,
though pathologies of the liver, spleen and bones are
also common (reviewed [242]). Several LSDs which fea-
ture neurodegeneration are associated with mutations in
hydrolytic enzymes responsible for the processing of
specific lipids, resulting in their build up within the lyso-
somal lumen. Examples include the Neuronal ceroid
lipofuscinoses (NCLs), a family of 14 genetically distinct,
autosomal recessive LSDs that present juvenile onset vi-
sion loss, seizures, cognitive decline and motor dysfunc-
tion, unified by the accumulation within neuronal
lysosomes of auto-fluorescent lipofuscin, a heterogenous
mixture of oxidised lipids, proteins and carbohydrates
[243]. Neuroinflammation and neuronal death are seen
in juvenile onset Sandhoff disease and heterogenous on-
set Tay-Sach’s disease, both GM2-gangliosidosis disor-
ders caused by accumulation GM2-gangliosides within
the lysosomal lumen [244].
The sphingolipidosis Gaucher’s disease is of particular
interest due to implications in the pathogenesis of PD.
Autosomal recessive Gaucher’s disease is characterised
by the accumulation of glucosylceramide (GluCer) due
to mutation of the β-glucocerebrosidase (GBA) gene
[245], with progressive neurological dysfunction is seen
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type III forms. In addition to accumulation of lysosomal
GluCer, misfolded mutant GBA accumulates in the ER
[246, 247], with mutant GBA associated with activated
unfolded protein response in model systems [248–250].
There is a wealth of emerging data to suggest a strong
association between impediment of lysosomal enzymatic
function and synucleinopathies, in particular PD [251].
Genetic studies of PD patients have identified a strong
association with heterozygosity for GBA loss-of-function
mutations and increased risk of developing PD [252].
Both wild type alpha-synuclein and PD associated var-
iants interact with lipids [253]. Dysfunction of GBA can
disrupt alpha-synuclein function [254] and exacerbate its
aggregation [255], with GluCer stabilising the peptide in
oligomeric species and promoting its aggregation [256].
Alpha-synuclein is degraded through the lysosome via
chaperone-mediate autophagy (see above) [257, 258].
Further still, accumulation of alpha-synuclein itself is
able to inhibit lysosomal GBA function, suggesting a
feed-forward loop of alpha-synuclein aggregation pro-
moting lysosomal dysfunction and further accumulation
of aggregated protein [256]. Intriguingly, PD-associated
GBA variants GBAL444P and GBAN370S can also impede
normal PRKN ubiquitination of mitochondrial substrates
[259, 260], and heterozygous GBAL444P mutations de-
crease the delivery of the mitochondria to lysosomes
[261]. As mitochondrial dysfunction is not observed in
heterozygous GBA knockout neurons [262] PD-
associated GBA variants may convey specific gain-of-
function effects in neurons, aside from lysosomal func-
tion. Due to the implications of GBA-associated lyso-
somal dysfunction and PD-associated pathologies,
GluCer synthesis and metabolism have become promis-
ing targets for therapeutic intervention [254, 263–265],
as have molecules such as ubiquitin ligase NEDD4,
which target alpha-synuclein for lysosomal destruction
[266].
Lysosomal dysfunction can also contribute to neurode-
generation through mutations that do not directly affect
hydrolytic enzymes. Niemann-Pick disease type C (NPC)
is a juvenile onset neurodegenerative condition with
death occurring in young adulthood, primarily effecting
the cerebellum, associated with accumulation of a range
of lipids within the lysosomal lumen including choles-
terol, sphingomyelin and sphingosine [267–271]. The
disorder has two genetically distinct forms; NPC1 is a
sterol-sensing transmembrane protein acidic compart-
ments [50, 51, 272] and rarer mutations in NPC2 that
disrupt a lysosomal soluble peptide with a cholesterol
binding domain [52, 53, 273]. As NPC1 is expressed in
most cell types, why neurons are particularly vulnerable
to its dysfunction is unclear. Experimental data has sug-
gested defective regulation of lysosomal calcium maycontribute to NPC associated phenotypes, with increased
storage of lysosomal sphingosine causing a reduction in
luminal calcium levels, subsequent accumulation of fur-
ther lipids and defects in endocytic trafficking [274].
Since NPC shares formation of the hyperphosphorylated
Tau neurofibrillary tangles typically seen in AD and PD
[275], understanding the mechanistic role of NPC1/2 in
lysosome function may have broader implications for
other neurodegenerative diseases and their treatment.
Lysosome positioning
The positioning of lysosomes within a cell is intertwined
with the function of these vesicles, particularly with re-
gard to acidification of the lumen. In non-polarised cells,
lysosomes are distributed into two groups; a relatively
stationary perinuclear “cloud” [276] where early endo-
somes mature through to lysosomes, and a highly motile
population in the periphery [277]. Lysosome transporta-
tion to the periphery generally occurs along microtubule
networks, with anterograde transport to the periphery
mediated by kinesin motor proteins [278], and returning
retrograde transport by the dynactin motor complex
[279]. Lysosome distribution differs somewhat in highly
polarised neurons, where the vast length and volume of
many axons requires effective delivery of acidified lyso-
somes. Though lysosomes can be detected throughout
the soma, axon, dendrites and synapses of neurons, their
positioning appears to define their function. Mature,
acidified lysosomes are enriched in the soma, with a de-
creasing gradient of acidity along the distal-proximal
length of the axon, suggesting degradation within lyso-
somes occurs in the cell body [280, 281]. Directionality
of lysosome transport within the axon has not been fully
resolved, in part due to differences in the assays used for
their detection [282]. Further research into the basic
neurobiology of lysosome maintenance and trafficking is
long overdue and would enable us to better understand
neurodegenerative disease.
Abnormal transport and positioning of lysosomes may
contribute towards the pathogenesis of AD, particularly
as disruption of the endo-lysosomal system is one of the
earliest detectable histopathological features [206]. Swol-
len, dystrophic neurites are a common histopathological
feature of AD [283, 284], with lysosomes and related
vesicles found to accumulate within these axonal swel-
lings. Curiously, such lysosome enriched swellings are
often in regions proximal to amyloid plaques in patient
brains [285–287] and rodent models of the disease
[288]. Whether accumulation of lysosomes cause amyl-
oid pathology, or a secondary event downstream of
plaque formation, remains unanswered. It is conceivable
that plaques and the neuroinflammation may alter local
intra-axonal processes such as transportation, however
emerging experimental data suggests that dysregulation
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accumulation. Proteins in the c-Jun N-terminal kinase-
interacting proteins (JIP) family of conserved mitogen
activated protein kinases (MAPKs) regulate microtubule
mediated transport of cargos along axons [289, 290].
Mutation of JIP3 causes accumulation of lysosomal vesi-
cles, amyloid processing enzymes and increased produc-
tion of toxic species of Aβ in an AD mouse model [291].
Further links between AD pathology and lysosome func-
tion can be found in the function of PSEN proteins.
Early onset AD patients with PSEN1 or 2 mutations
present elevated lysosomal pathology levels or lysosome
associated pathology [292]. Experimental disruption of
PSEN1 in cell culture models results in reduced assem-
bly of the vacuolar-type H+ ATPase (vATPase) complex
at the lysosomal membrane and subsequent failure of
the lumen to reach correct acidic pH [293]. Consequen-
tially, lysosomal acid-sensitive hydrolytic enzymes have
reduced function and increased efflux of luminal Ca2+.
Taken together, evidence of accumulation of axonal ly-
sosomes, increasing amyloid plaque burden and lyso-
somal dysfunction associated hereditary AD genes are
suggestive that impaired lysosomal positioning may be a
contributing factor in AD that warrants further investi-
gation. Furthermore, as mislocalisation of lysosomes has
also been reported in cellular models of HD [294] and
ALS associated mutant dynactin-p150glued [295], disrup-
tion of their trafficking may be a common pathogenic
event in neurodegeneration.
Conclusions and future perspectives
Changes in autophagy, mitophagy and endo-lysosomal
processes have been implicated in most neurodegenera-
tive diseases, however their contribution is still only par-
tially defined, with several outstanding questions.
Though the regulatory processes underpinning autoph-
agy are well understood with regard to starvation, its
regulation in neurons in health and disease is poorly de-
fined. The initiating signals for upregulation of autoph-
agy in times of neurotoxic stress are not well
understood, particularly how the right balance between
homeostatic autophagy and the clearance of toxic mater-
ial is achieved. More so, it is not entirely clear if autoph-
agy is indeed protective, or is instead contributing to
neuronal stress and destruction. This is in part due to
gaps in our basic understanding of the cellular mechan-
ism driving autophagy. Though a peripheral origin and
retrograde transport of autophagosomes has been dem-
onstrated in tissue culture experiments [67], the source
of the phagophore isolation membrane in neurons is not
clear and requires further description in vivo. Experi-
ments in Drosophila have also suggested an important
role for microautophagy in the maintenance of synapses
[122], a highly vulnerable neuronal compartment, andthis process warrants further investigation in the context
of neurodegenerative disease.
Despite extensive exploration of the function of PINK1
and PRKN in Parkinsonisms, robust evidence for defect-
ive mitophagy as a direct cause of pathology in patient
brains is lacking. It is clear that PINK1 and PRKN have
independent roles outside of mitophagy [296, 297], and
furthermore, there is evidence to suggest that basal
mitophagy can occur independently of PINK1 or PRKN
[298, 299]. The importance of PINK1/PRKN mediated
mitophagy to the viability of dopaminergic neurons in
the substantia nigra thus needs to be clarified. The link
between mitophagy and neuroinflammation is not well
characterised, but new findings indicate that the meta-
bolic state of microglia influence their activation [162]
and this can be regulated by mitochondrial turnover
[159]. The relationship between mitochondrial quality
control in glial cells and neurodegenerative disorders
may reflect the convergence of two key processes in neu-
rodegenerative disorders and therefore requires further
investigation.
It is curious why specific mechanisms within the endo-
somal pathway appear to be dysregulated in different
neurological conditions, suggesting divergent patho-
logical roles in neurodegeneration. While EE dysfunction
appears to be a characteristic feature of multiple neuro-
degenerative diseases, RE is primarily implicated in HD
and AD, whereas LE pathway dysfunction is largely
restricted to PD. Disruption of synaptic receptor recyc-
ling, observed when the RE is compromised [231], may
be of a significant importance to medium spiny neurons
and cortical/hippocampal neurons that underpin learn-
ing and memory through spine remodelling. The LE
pathway may on the other hand play a more prominent
feature in dopaminergic neurons, where the disposal of
mitochondria and alpha-synuclein is prioritised [156,
300]. It is currently unclear why EE dysfunction appears
to be a pathological feature of many different diseases.
Does EE dysfunction always lead to lysosomal problems
downstream or is the LE system adaptable enough to
correct itself despite endocytosis and sorting issues? Cu-
mulative evidence supports the latter, suggesting that
lack of LE-lysosome fusion can to some degree be com-
pensated for by autophagic clearance. The endosomal
pathway is a dynamic continuum and a shift in its bal-
ance may result in neuronal demise, as evidenced by
both causative and enhanced disease risk associated
mutations.
Finally, abundant data suggests that defects in autoph-
agy and the endo-lysosomal system contribute to dis-
ease, supporting the concept that their stimulation is a
feasible target for therapeutic intervention in neurode-
generation. Several pharmacological modifiers of au-
tophagy with blood brain barrier permeable properties
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use [98, 99, 301, 302]. These are generally not consid-
ered appropriate for long-term use due to global alter-
ations of essential cellular processes [303]. Identifying
potent, neuro-specific modulators of autophagy and
endo-lysosomal function will be essential to determine if
these pathways are truly viable targets for therapeutics,
in order to ultimately treat devastating neurodegenera-
tive disorders.
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Protein 7; FIP200: Focal Adhesion Kinase Family Kinase-Interacting Protein Of
200KDa; FTD: Frontotemporal Dementia; GAK: Cyclin G Associated Kinase;
GBA: β-glucocerebrosidase; GDP: Guanosine Diphosphate; GEF: Guanine
Nucleotide Exchange Factor; GluCer: Glucosylceramide; GTP: Guanosine
Triphosphate; GWAS: Genome Wide Association Study; HAP40: HTT
associated protein 40; HD: Huntington’s disease; HSC70: Heat Shock Protein
Family A (Hsp70) Member 8; HSP90: Heat Shock Protein 90; HTT: Huntingtin;
iPSC: induced Pluripotent Stem Cell; JIP: c-Jun N-terminal kinase-interacting
proteins; LAMP2A: Lysosome-Associated Membrane Protein 2A; LC3-
I: Microtubule Associated Protein 1 Light Chain 3 – non-lipidated; LC3-
II: Microtubule Associated Protein 1 Light Chain 3 -
phosphatidylethanolamine lipidated; LE: Late Endosome; LRRK2: Leucine Rich
Repeat Kinase 2; MAPK: Mitogen Activated Protein Kinases; MEF2D: Myocyte
Enhancer Factor 2D; MFN1: Mitofusin 1; MOM: Mitochondrial Outer
Membrane; mTOR: mammalian Target Of Rapamycin; mTORC1: mammalian
Target Of Rapamycin Complex 1; MVB: Multi-Vesicular Body;
NADH: Nicotinamide adenine dinucleotide; NBR1: Neighbour Of BRCA1 Gene
1 Autophagy Cargo Receptor; NCL: Neuronal ceroid lipofuscinosis;
NDP52: Nuclear Domain 10 Protein 52/ Calcium Binding And Coiled-Coil
Domain 2; NEDD4: Neural Precursor Cell Expressed, Developmentally Down-
Regulated 4; NPC: Niemann-Pick disease type C; OPTN: Optineurin;
p62: Phosphotyrosine-Independent Ligand For The Lck SH2 Domain Of 62
KDa / Sequestosome-1; PARL: Presenilin Associated Rhomboid-Like;
PD: Parkinson’s disease; PI(3)P: Phosphatidylinositol 3-phosphate;
PINK1: PTEN-Induced Kinase 1; poly-Q: poly-Glutamine; PRKN: Parkin RBR E3
Ubiquitin Protein Ligase; PSEN: Presenlin; RAB: GTPase RAB guanosine
triphophatase; RE: Recycling Endosome; Rheb: RAS homolog enriched in the
brain; Rhes: RAS homolog enriched in the striatum; RIN: RAS and RAB
interactor 1; SH3TC2: SH3 domain and tetratricopeptide repeats 2;
SNARE: Soluble N-ethylmaleimide-sensitive fusion protein attachment protein
Receptor; SNX: Sorting Nexin; SORCS1: Sortilin Related VPS10 Domain
Containing Receptor 1; SORL1: Sortilin Related Receptor 1;
SYNJ1: Synaptojanin 1; TAX1BP1: TAX1 Binding Protein 1; TBK1: TANK Binding
Kinase 1; UA: Urolithin A; UCHL-1: Ubiquitin carboxyl-terminal esterase L1;
ULK1: Unc-51-like Autophagy Activating Kinase 1; vATPase: vacuolar-Type H+
ATPase; VPS: Vacuolar Protein Sorting
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